
The suit alleges that the Thousand Oaks biotech firm offered medical providers kickbacks to boost sales of Aranesp, leading to fraudulent claims for reimbursement from Medicaid and other insurers.
"Anemia drugs have come under increasing fire after a series of studies found that high doses can lead to increased risk of heart attack, stroke, heart failure and tumor growth in some patients. In 2007, the Food and Drug Administration issued a "black-box warning" for Amgen's anemia medications -- the strongest warning possible about potential side affects."
"The Associated Press reported late Friday that a new study raised fresh safety concerns about the drugs, finding that Aranesp nearly doubled the risk of stroke in people with diabetes and chronic kidney problems who are not yet sick enough to need dialysis."
Bye, Bye Amgen....
You're in Easy Mode. If you prefer, you can use XHTML Mode instead. |